Oral fingolimod (FTY720) therapy reduces blood brain barrier breakdown, microglial activation, and leukocyte recruitment in a focal DTH model of multiple sclerosis
Egile Nagusiak: | Anthony, D, Sibson, N, Losey, P, Piani, D, Leppert, D |
---|---|
Formatua: | Conference item |
Argitaratua: |
2009
|
Antzeko izenburuak
-
The antineoplastic properties of FTY720: Evidence for the repurposing of fingolimod
nork: Patmanathan, S.N., et al.
Argitaratua: (2015) -
Investigation of immune and CNS-mediated effects of fingolimod in the focal delayed-type hypersensitivity multiple sclerosis model.
nork: Anthony, D, et al.
Argitaratua: (2014) -
The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage
nork: Stradner Martin H, et al.
Argitaratua: (2011-12-01) -
Ameliorative effects of Fingolimod (FTY720) on microglial activation and psychosis-related behavior in short term cuprizone exposed mice
nork: Siyao Li, et al.
Argitaratua: (2023-07-01) -
The Immunosuppressant Fingolimod (FTY720) for the Treatment of Mechanical Force-Induced Abnormal Scars
nork: Masayo Aoki, et al.
Argitaratua: (2020-01-01)